Primary Multiple Myeloma Who Achieved MRD Negativity After Induction Therapy, ASCT or Not

This trial investigates the best maintenance strategy after stem cell transplant for people with multiple myeloma who achieved very deep remission (MRD negativity) after induction treatment — testing whether transplant or continued drug treatment offers the best long-term outcomes. **You may be eligible if...** - You are between 18 and 70 years old with a new diagnosis of multiple myeloma - After 4–6 cycles of induction therapy, you achieved a very good partial response or better, including MRD negativity (no detectable cancer cells at a very sensitive level) - Your ECOG performance score is 0–2 and major organ function is within normal limits - Your expected survival is more than 3 months **You may NOT be eligible if...** - You have two or more high-risk genetic changes in your myeloma cells (such as del17p, t(4;14), or amp1q) - You have plasma cell leukemia or cancer in the central nervous system - You have had another cancer in the past 5 years - You have HIV, active tuberculosis, or active hepatitis A, B, or C - You have serious uncontrolled infections, heart failure, or diabetes Talk to your doctor to see if this trial is right for you.